Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Evinacumab in Healthy Japanese and Caucasian Subjects
NCT03146416Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- May 2017
- Primary completion
- Jun 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of evinacumab in hypercholesterolemia (5 cohorts), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Incidence of Treatment Emergent Adverse Events and Severity of Treatment Emergent Adverse Events. Started May 2017; status: completed.
02
Drugs
evinacumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT03146416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03146416.